Adagene, Inc. (($ADAG)) announced an update on their ongoing clinical study. Study Overview: Adagene, Inc. (ADAG) is conducting a Phase 1b/2 ...

Radiopharm Theranostics Limited (($AU:RAD)) announced an update on their ongoing clinical study. Study Overview: Radiopharm Theranostics Limited ...

The first-in-class FGFR2b antibody bemarituzumab extends overall survival in patients with advanced gastric cancer, but the ...

Targeting TIGIT with tiragolumab does not improve outcomes over atezolizumab plus bevacizumab in untreated advanced ...

Takeda will pay $1.2 billion upfront, including a $100 million equity investment, for rights to two programs and the option to license a third candidate.

Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the ...

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...

Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) ...

The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...

Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death by 60% and the risk of death by 50% in ...

The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...